Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer

Autor: Taro Funakoshi, Keita Fukuyama, Shigemi Matsumoto, Yoshihiro Yamamoto, Masahiro Yoshioka, Akira Yokoyama, Masashi Kanai, Tadayuki Kou, Masashi Tamaoki, Sachiko Minamiguchi, Yuichi Sakamori, Motoo Nomura, Kenshiro Hirohashi, Atsushi Yamada, Masakazu Nishigaki, Pham Nguyen Quy, Takahiro Yamada, Tomohiro Kondo, Keitaro Doi, Junichi Matsubara, Manabu Muto
Rok vydání: 2020
Předmět:
0301 basic medicine
Oncology
Adult
Male
Cancer Research
medicine.medical_specialty
druggable genomic alteration
Genomic profiling
Colorectal cancer
medicine.medical_treatment
gastrointestinal cancer
Druggability
03 medical and health sciences
Young Adult
0302 clinical medicine
Clinical Research
Internal medicine
Neoplasms
precision cancer medicine
medicine
Biomarkers
Tumor
Humans
actionable genomic alteration
Gastrointestinal cancer
Molecular Targeted Therapy
Prospective Studies
Stage (cooking)
Precision Medicine
Aged
Aged
80 and over
Chemotherapy
business.industry
comprehensive genomic profiling
Gene Expression Profiling
Cancer
High-Throughput Nucleotide Sequencing
General Medicine
Sequence Analysis
DNA
Middle Aged
medicine.disease
030104 developmental biology
030220 oncology & carcinogenesis
Female
Original Article
business
Companion diagnostic
Zdroj: Cancer Science
ISSN: 1349-7006
Popis: Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies. However, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic (F1CDx) assay. The primary outcome was the detection rate of at least one actionable/druggable cancer genomic alteration. Actionable/druggable cancer genomic alterations were determined by the F1CDx report. An institutional molecular tumor board determined the molecular‐based recommended therapies. A total of 197 patients were enrolled from October 2018 to June 2019. CGP success rate was 76.6% (151 of 197 patients), and median turnaround time was 19 days (range: 10‐329 days). Actionable and druggable cancer genomic alterations were reported in 145 (73.6%) and 124 (62.9%) patients, respectively. The highest detection rate of druggable genomic alterations in gastrointestinal cancers was 80% in colorectal cancer (48 of 60 patients). Molecular‐based recommended therapies were determined in 46 patients (23.4%). CGP testing would be a useful tool for the identification of a potentially effective first‐line chemotherapy.
Comprehensive genomic profiling (CGP) testing by next‐generation sequencing has been introduced into clinical practice as part of precision cancer medicine to select effective targeted therapies; however, whether CGP testing at the time of first‐line chemotherapy could be clinically useful is not clear. We conducted this single‐center, prospective, observational study to investigate the feasibility of CGP testing for chemotherapy‐naïve patients with stage III/IV gastrointestinal cancer, rare cancer, and cancer of unknown primary, using the FoundationOne® companion diagnostic assay. We found that CGP testing could be feasible in Japanese clinical practice for chemotherapy‐naïve patients with these cancers, and that CGP testing might be a useful tool to identify a potentially effective first‐line treatment, which will lead to the establishment of precision cancer medicine.
Databáze: OpenAIRE
Externí odkaz: